Arcutis BiotherapeuticsARQT
ARQT
About: Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Employees: 342
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
207% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $4.26M
113% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 30
15% more funds holding
Funds holding: 207 [Q4 2024] → 239 (+32) [Q1 2025]
9% more capital invested
Capital invested by funds: $1.79B [Q4 2024] → $1.95B (+$160M) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
4.7% less ownership
Funds ownership: 110.08% [Q4 2024] → 105.38% (-4.7%) [Q1 2025]
20% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 81
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
23%
upside
Avg. target
$19
30%
upside
High target
$20
37%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Goldman Sachs Richard Law | 23%upside $18 | Neutral Initiated | 25 Jul 2025 |
Needham Serge Belanger | 37%upside $20 | Buy Reiterated | 23 May 2025 |
Financial journalist opinion
Based on 4 articles about ARQT published over the past 30 days
Negative
Zacks Investment Research
9 hours ago
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 week ago
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
Arcutis announced today that it will report Q2 2025 financial results and provide a business update on Aug 6, 2025 after the U.S. financial markets close.
Neutral
Investors Business Daily
1 week ago
Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196%
Arcutis stock is setting up in a base with the company's earnings report due around mid-August.
Neutral
GlobeNewsWire
3 weeks ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 14,000 restricted stock units of Arcutis' common stock to two newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Seeking Alpha
1 month ago
Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction
Arcutis Biotherapeutics' ZORYVE (roflumilast) offers superior efficacy and safety over current topical treatments for mild-to-moderate atopic dermatitis. The atopic dermatitis market is large and shifting away from steroids, positioning Arcutis to capture significant share, especially via primary care channels. Arcutis is financially strong, with over 30 months of cash runway and no anticipated need for equity dilution before reaching profitability in 2026.
Neutral
GlobeNewsWire
1 month ago
Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis
The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with mild to moderate atopic dermatitis (AD) Recommendation reflects ZORYVE's proven efficacy, safety, and tolerability as a next-generation, steroid-free, topical phosphodiesterase-4 (PDE4) inhibitor Among newly evaluated branded topical therapies, ZORYVE is the only treatment with a strong recommendation for adults with mild to moderate atopic dermatitis in AAD's focused guideline update ZORYVE is the first FDA-approved branded topical PDE4 inhibitor indicated for AD, plaque psoriasis, and seborrheic dermatitis AD impacts over 16 million adults in the United States WESTLAKE VILLAGE, Calif, June 26, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.15% has received a strong recommendation in the focused guideline update for the management of adult AD from AAD. The recommendation highlights ZORYVE's ability to deliver clinically meaningful improvements in pruritus and disease severity, its favorable tolerability profile, and low rates of treatment discontinuation, offering adults and pediatric patients 6 years of age and older with mild to moderate AD an effective, non-steroid option for daily disease management.
Positive
Seeking Alpha
1 month ago
Arcutis Biotherapeutics: Another Approval Under Their Belt
Shares of Arcutis Biotherapeutics have fallen by 5% since my March update. Zoryve's 4th approval in scalp & body psoriasis should further boost sales and contribute to the "portfolio effect". IP developments suggest the company's protection for Zoryve, though related to formulation instead of composition of matter, is stronger than originally thought.
Positive
Seeking Alpha
1 month ago
Arcutis: Out Of The Woods, Ready For Commercialization
Arcutis Biotherapeutics stands out in biotech for its impressive factor grades, which are rare in this sector. The recent FDA approval of ZORYVE Topical foam opens a significant revenue and profitability opportunity for Arcutis. FDA approval removes a major risk, allowing the company to commercialize and market its drug after years of costly R&D.
Neutral
GlobeNewsWire
1 month ago
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Four-week Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitis Atopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis develop symptoms within their first year WESTLAKE VILLAGE, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first child has been enrolled in a Phase 2 open-label study, INTEGUMENT-INFANT, evaluating the safety and tolerability of investigational ZORYVE (roflumilast) cream 0.05% in infants aged 3 months to less than 24 months with atopic dermatitis (AD) applied once daily over a four-week period.
Neutral
GlobeNewsWire
1 month ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 72,000 restricted stock units of Arcutis' common stock to nine newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 2, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™